359 KB57 KB199420252013Jurič, Damijana MojcaŽiberna, Lovroštevilka:2letnik:52str. 255-270ISSN:0025-8121COBISSID:30647769URN:URN:NBN:SI:doc-P062N4TZslMedicinski razglediMedicinski razgledihistaminhistaminehistamine receptor type 3histaminski receptor tipa 3intracellular signalingnevrofarmakologijaosrednje živčevjeHistaminski receptor tipa 3 - od gena do terapevtske tarče| Histamine receptor type 3 - from gene to drug target|Histamine receptor type 3 was discovered in 1983 by Schwartz and coworkers and cloned in 1999. The expression ofhistamine receptor type 3 is largely confined to the central nervous system, where differential transcriptional and posttranscriptional processing lead to a high degree of molecular and functional heterogeneity. Histamine receptor type 3 has unique properties including constitutive activity in viva and the recruitment of plasticity-related signal transduction pathways, including Gai/0 - proteins, adenylyl cyclase, phospholipase Az, mitogen-activated protein kinase and Akt/glycogen synthase kinase 3 signalling. These make the histamine receptor type 3 the most prominent target for histaminergic drug development. Histamine receptor type 3 can function both as an auto receptor and as a heteroreceptor. As an autoreceptor on histaminergic neurons, histamine receptor type 3 activation inhibits celi firing, histamine synthesis and release. As a presynaptic heteroreceptors on other neurons, histamine receptors type 3 abundantly control the outf1ow of various neurotransmitters, including biogenic amines, acetylcholine, glutamate and y-amino butyric acid. The histamine receptor type 3 functioning is associated with cognition, behaviour, wakefulness and sleep regulation, locomotion, appetite regulation and pa in perceptionTEXTznanstveno časopisjejournalsSlovenian National E-content AggregatorNational and University Library of SloveniaDruštvo Medicinski razgledi